|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0110 AUD | -8.33% |
|
-8.33% | -26.67% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.3M 3.78M 3.53M 3.24M 6.08M 413M 41.85M 16.37M 204M 16.16M 15.81M 705M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.24M 5.49M 5.11M 4.69M 8.81M 599M 60.69M 23.74M 296M 23.43M 22.92M 1.02B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | -8.33% | ||
| 1 week | -8.33% | ||
| Current month | -8.33% | ||
| 1 month | -21.43% | ||
| 6 months | -26.67% | ||
| Current year | -26.67% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.01 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.78 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -8.33% | -8.33% | -38.89% | -77.55% | 4.31M | ||
| +1.68% | +2.13% | +16.17% | +77.49% | 48.36B | ||
| +1.52% | +2.95% | +60.39% | +112.28% | 35.8B | ||
| -0.09% | -0.66% | -8.03% | +31.90% | 11.83B | ||
| -0.05% | -3.10% | +13.50% | +77.95% | 11.48B | ||
| -0.37% | -0.37% | +37.53% | +142.08% | 9.01B | ||
| +0.18% | +0.58% | +49.62% | -9.13% | 6.99B | ||
| +0.95% | -2.00% | +12.78% | +32.58% | 6.7B | ||
| +0.18% | -1.77% | +2.36% | +172.36% | 6.42B | ||
| +3.51% | -10.57% | -31.55% | +0.09% | 5.3B | ||
| Average | -0.08% | -1.09% | +11.39% | +56.01% | 14.19B | |
| Weighted average by Cap. | +1.11% | -0.14% | +25.52% | +81.62% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.56M 3.13M 2.91M 2.67M 5.02M 341M 34.6M 13.53M 168M 13.35M 13.07M 583M | 1.19M 832K 731K 681K 625K 1.17M 79.75M 8.09M 3.16M 39.37M 3.12M 3.05M 136M |
| Net income | -5.8M -4.05M -3.56M -3.32M -3.05M -5.72M -389M -39.41M -15.42M -192M -15.21M -14.89M -664M | -5.94M -4.15M -3.65M -3.4M -3.12M -5.87M -398M -40.4M -15.81M -197M -15.59M -15.26M -680M |
| Net Debt | 759K 530K 466K 434K 399K 749K 50.86M 5.16M 2.02M 25.11M 1.99M 1.95M 86.84M | 2.77M 1.94M 1.7M 1.59M 1.46M 2.74M 186M 18.84M 7.37M 91.72M 7.27M 7.11M 317M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/07/26 | A$0.0110 | -8.33% | 169,956 |
| 24/07/26 | A$0.0120 | 0.00% | 30,408 |
| 23/07/26 | A$0.0120 | 0.00% | 111,592 |
| 22/07/26 | A$0.0120 | 0.00% | 339 |
| 21/07/26 | A$0.0120 | 0.00% | 700,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















